Guidant battle signals another brisk year for biotech mergers
Strong profits, low interest rates, and hordes of cash have sparked a wave of mergers that underlie Boston Scientific's battle to buy a rival medical device maker. (Full article: 815 words)
This article is available in our archives:
Globe Subscribers
FREE for subscribers
Subscribers to the Boston Globe get unlimited access to our archives.
Not a subscriber?
Non-Subscribers
Purchase an electronic copy of the full article. Learn More
- $4.95 1 article
- $9.95 4 articles
- $25.95 Monthly
